Muscle atrophy Sarcopenia
Conditions
Interventions
Controlled, randomized, double blind, crossover clinical trial with two intervention periods, in which participants will be randomly allocated into two conditions, receiving angiotensin 1 7 complexed
Sponsors
Universidade Federal de Ouro Preto
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Eligibility
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: older adults aged 65 years or older residing in the cities of ouro preto and mariana; presenting skeletal muscle loss; presenting any level of sarcopenia including severe sarcopenia; who agree to participate in the proposed intervention
Exclusion criteria
Exclusion criteria: participants who do not meet the inclusion criteria; who refuse to sign the informed consent form; who do not fully complete the research instruments; who do not demonstrate interest in participating in the intervention; individuals with severe liver disease; limiting cardiovascular disorders; severe renal impairment; dementia; parkinson disease; severe neuropsychological disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find improvements in muscle mass, muscle function, and related parameters in older adults with sarcopenia undergoing supplementation with angiotensin 1 7 combined with physical exercise | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
BR
Contacts
Public ContactLenice Becker
Universidade Federal de Ouro Preto
Outcome results
None listed